{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:49:48Z","timestamp":1793321388650,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":586,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA078902"],"award-info":[{"award-number":["CA078902"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["HL036444"],"award-info":[{"award-number":["HL036444"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA015704"],"award-info":[{"award-number":["CA015704"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ricerca Sanitaria Finalizzata","award":["RF-PIE-2008-1206999"],"award-info":[{"award-number":["RF-PIE-2008-1206999"]}]},{"name":"Ricerca Sanitaria Finalizzata","award":["RF-PIE-2009-1491359"],"award-info":[{"award-number":["RF-PIE-2009-1491359"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.bbmt.2013.06.002","type":"journal-article","created":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T14:00:50Z","timestamp":1370959250000},"page":"1340-1347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Fludarabine and 2-Gy TBI is Superior to 2\u00a0Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial"],"prefix":"10.1016","volume":"19","author":[{"given":"Brian","family":"Kornblit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Storek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Chauncey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn B.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Bethge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"H\u00fcbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Bouvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry E.","family":"Storer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2013.06.002_bib1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1182\/blood.V74.3.1139.1139","article-title":"Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts","volume":"74","author":"Storb","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib2","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood.V89.8.3048","article-title":"Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation","volume":"89","author":"Storb","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0360-3016(93)90207-C","article-title":"Marrow toxicity of fractionated versus single dose total body irradiation is identical in a canine model","volume":"26","author":"Storb","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bbmt.2013.06.002_bib4","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib5","article-title":"Low dose TBI conditioning for hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: influence of fludarabine or cytoreductive autografts on outcome","volume":"100","author":"Sandmaier","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2141.2005.05363.x","article-title":"Allogeneic peripheral blood stem cell graft composition affects early T cell chimaerism and later clinical outcomes after nonmyeloablative conditioning","volume":"128","author":"Panse","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.06.002_bib7","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1182\/blood.V92.10.3515","article-title":"Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient","volume":"92","author":"Petersdorf","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib8","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood-2003-02-0482","article-title":"HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies","volume":"102","author":"Maris","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib9","unstructured":"The Revised Common Toxicity Criteria: Version 2.0. DCTD, NCI, NIH, DHHS,\u00a01999."},{"key":"10.1016\/j.bbmt.2013.06.002_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/bbmt.2002.v8.pm12374456","article-title":"Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study","volume":"8","author":"Junghanss","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.002_bib11","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.002_bib12","series-title":"Hematopoietic Cell Transplantation","first-page":"515","article-title":"Graft-versus-host disease","author":"Sullivan","year":"1999"},{"key":"10.1016\/j.bbmt.2013.06.002_bib13","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1182\/blood.V97.11.3380","article-title":"Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation","volume":"97","author":"Storek","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clim.2004.07.006","article-title":"Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)","volume":"113","author":"Storek","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bbmt.2013.06.002_bib15","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","article-title":"Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib16","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib17","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"Niederwieser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.TP.0000071862.42835.76","volume":"76","author":"Keil","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2013.06.002_bib19","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2005.08.136","article-title":"Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning","volume":"23","author":"Baron","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.06.002_bib20","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/blood-2004-04-1506","article-title":"Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"104","author":"Baron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/leu.2011.244","article-title":"Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation","volume":"26","author":"Breuer","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2013.06.002_bib22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbmt.2006.06.003","article-title":"Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome","volume":"12","author":"Alyea","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.002_bib23","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib24","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.bbmt.2011.12.581","article-title":"Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure","volume":"18","author":"Freytes","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.002_bib25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2003-02-0342","article-title":"Graft-versus-leukemia reactions in allogeneic chimeras","volume":"103","author":"Kolb","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nri999","article-title":"Alloreactive killer cells: hindrance and help for haematopoietic transplants (Review)","volume":"3","author":"Parham","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bbmt.2013.06.002_bib27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbmt.2009.01.018","article-title":"What is the role for donor NK cells after nonmyeolablative conditioning?","volume":"15","author":"Baron","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.002_bib28","doi-asserted-by":"crossref","first-page":"e55876","DOI":"10.1371\/journal.pone.0055876","article-title":"Kinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioning","volume":"8","author":"De","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bbmt.2013.06.002_bib29","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.06.002_bib30","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2010.89","article-title":"Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy","volume":"24","author":"Ysebaert","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2013.06.002_bib31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.06.002_bib32","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringd\u00e9n","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.06.002_bib33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.leu.2403745","article-title":"Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis","volume":"19","author":"Dreger","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2013.06.002_bib34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.exphem.2012.10.008","article-title":"Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study","volume":"41","author":"Michallet","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2013.06.002_bib35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bjh.12299","article-title":"Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD","volume":"161","author":"Takahashi","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.06.002_bib36","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood-2011-09-380436","article-title":"Durable donor engraftment after radioimmunotherapy using a-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113002437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113002437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:44:30Z","timestamp":1761057870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879113002437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1083879113002437"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.06.002","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fludarabine and 2-Gy TBI is Superior to 2\u00a0Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}